-
Tytuł:
-
Accelerating vein-to-vein cell therapy workflows with new bioanalytical strategies.
-
Autorzy:
-
Flint GT; Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY 12208, USA.
Drake PR; Stack Family Center for Biopharmaceutical Education and Training (CBET), Albany College of Pharmacy and Health Sciences, 257 Fuller Road, Albany, NY 12203, USA.
Goetz JP; Stack Family Center for Biopharmaceutical Education and Training (CBET), Albany College of Pharmacy and Health Sciences, 257 Fuller Road, Albany, NY 12203, USA.
Albaker MM; Stack Family Center for Biopharmaceutical Education and Training (CBET), Albany College of Pharmacy and Health Sciences, 257 Fuller Road, Albany, NY 12203, USA.
Rosenberg JN; Stack Family Center for Biopharmaceutical Education and Training (CBET), Albany College of Pharmacy and Health Sciences, 257 Fuller Road, Albany, NY 12203, USA. Electronic address: .
-
Źródło:
-
Current opinion in biotechnology [Curr Opin Biotechnol] 2021 Oct; Vol. 71, pp. 164-174. Date of Electronic Publication: 2021 Aug 17.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Publication: London : Elsevier
Original Publication: London : Current Biology, c1990-
-
MeSH Terms:
-
Bioengineering*
Cell- and Tissue-Based Therapy*
Biotechnology ; Humans ; Stem Cells ; Workflow
-
Entry Date(s):
-
Date Created: 20210820 Date Completed: 20211111 Latest Revision: 20211111
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.copbio.2021.07.007
-
PMID:
-
34416662
-
Cell therapies represent a new era of treatment modalities for cancer. Through agile bioprocessing and bioengineering, patient-derived T-cells can be directed toward cancer biomarkers to impart a more robust and targeted immune response. In order to avoid delays in critical treatment timeframes, new bioanalytical tools are needed to accelerate, streamline, and maximize the throughput of T-cell bioprocessing. This review offers a survey of recent biotechnological advances supporting enhanced and expedited biomanufacturing workflows for autologous and allogeneic cell therapies, ranging from novel genetic engineering techniques and cell sorting platforms to stem cells and tumor organoid models. Collectively, these methods can increase the clinical impact of cancer therapeutics by improving the specificity, efficacy, and timely delivery of cell-based products.
(Copyright © 2021 Elsevier Ltd. All rights reserved.)
